Physicians' Academy for Cardiovascular Education

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore

Diabetes & Obesity in HFpEF: New targets in heart failure management

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Prof. Rudolf de Boer - Groningen, The Netherlands

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK

Mendelian randomization studies can inform study design of RCTs, to set up naturally randomized trials

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands
Prof. Stroes discusses the role of residual inflammatory risk in diabetes and CKD and how epigenetics could play a role in reducing this risk.

Prof. Stroes discusses the role of residual inflammatory risk in diabetes and CKD and how epigenetics could play a role in reducing this risk.

Physical activity associated with reduced risk of diabetes at high CVD risk

Literature - Aug. 13, 2018 - Kraus WE et al. - BMJ Open Diab Res Care 2018

A subanalysis of the NAVIGATOR-trial showed a significant association between physical activity and reduced risk of the development of diabetes in patients at high CVD risk, independent of gender.

Clinical genetic testing provides improved diagnosis of FH

News - Aug. 13, 2018

An Expert Consensus Panel recommends that clinical genetic testing becomes standard care for patients with definite or suspicion of FH, as well as for their at-risk relatives, to improve risk stratification, diagnosis and early treatment.

Bariatric surgery decreases risk of microvascular complications in obese diabetic patients

Literature - Aug. 9, 2018 - O’Brien R et al. - Ann Intern Med 2018
Obese patients with T2DM, who underwent bariatric surgery, had a two-fold risk reduction of microvascular complications compared with matched controls.

Obese patients with T2DM, who underwent bariatric surgery, had a two-fold risk reduction of microvascular complications compared with matched controls.

LDL-c reductions below 1.6 mmol/L provide additional vascular risk benefit

Literature - Aug. 8, 2018 - Sabatine MS et al. - JAMA Cardiol 2018
In a meta-analysis of statins and non-statins, LDL-c reductions reaching to a median of 0.5 mmol/L (21 mg/dL) in patients starting with median LDL-c levels of 1.6-1.8 mmol/L (63 mg/dL) are associated with lower risk of major vascular events.

In a meta-analysis of statins and non-statins, LDL-c reductions reaching to a median of 0.5 mmol/L (21 mg/dL) in patients starting with median LDL-c levels of 1.6-1.8 mmol/L (63 mg/dL) are associated with lower risk of major vascular events.

Novel antiarrhythmic drug safe but not clinically effective in patients with paroxysmal AF

Literature - Aug. 8, 2018 - Camm AJ et al. - Eur Heart J 2018

A randomized trial using continuous heart monitoring, showed that the selective I-kur-inhibitor S66913 was safe, but had no clinically meaningful effect in patients with symptomatic paroxysmal AF.

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

ARNI provided no additional benefit on renal function compared with ARB

Literature - Aug. 7, 2018 - Haynes R et al. - Circulation 2018; published online ahead of print

In patients with chronic kidney disease, sacubitril/valsartan had similar effects on renal function compared with irbesartan after 12 months of therapy. ARNI therapy did lower BP, NT-proBNP and troponin.

How much should Lp(a) be lowered to translate into meaningful CV benefit?

3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.

Statin exposure associated with idiopathic inflammatory myositis

Literature - Aug. 7, 2018 - Caughey GE et al. - JAMA Intern Med. 2018

Statin exposure was significantly associated with histologically confirmed idiopathic inflammatory myositis, suggesting that this potential risk should be taken into account when prescribing statins.

Diabetic patients with HF may particularly benefit from SGLT2 inhibitor therapy

Literature - Aug. 7, 2018 - Rådholm K et al. - Circulation 2018
Analyses of the CANVAS data show that in T2DM patients, canagliflozin reduced the risk of CV death or HF hospitalization particularly in patients with a history of HF at baseline.

Analyses of the CANVAS data show that in T2DM patients, canagliflozin reduced the risk of CV death or HF hospitalization particularly in patients with a history of HF at baseline.

Insufficient ground to add non-traditional risk factors to CVD risk assessment

News - Aug. 3, 2018

The US Preventive Services Task Force (USPSTF) found evidence that adding the non-traditional risk factors ABI, hsCRP and CAC could slightly improve current CVD risk assessment, but the clinical meaning is unknown.